摘要
目的观察乳腺Ⅰ号胶囊治疗乳腺增生症患者的临床应用效果。方法随机选取2015年4月~2016年5月我院收治的乳腺增生症患者97例,分为对照组与观察组。对照组48例,给予他莫昔芬治疗。观察组49例,给予乳腺Ⅰ号胶囊治疗。比较2组患者治疗有效率、不良反应发生率及血清性激素水平。结果观察组治疗有效率（93.88%）高于对照组（79.17%）,差异具有统计学意义（P〈0.05）。观察组不良反应发生率（6.12%）低于对照组（20.83%）,差异具有统计学意义（P〈0.05）。观察组E2、PRL、LH水平低于对照组,差异具有统计学意义（P〈0.05）。结论乳腺Ⅰ号胶囊可提高乳腺增生症患者临床疗效,降低不良反应发生率,改善患者血清性激素水平,值得推广。
Objective To observe the clinical curative effect of breast I capsule in treatment of cyclomastopathy.Methods 97 cases of patients with cyclomastopathy cured in our hospital from April 2015 to May 2016 were randomly selected and divided into control group and observation group.48 cases were divided into control group,and they were treated with tamoxifen.49 cases were divided into observation group,and they were divided into breast I capsule.The effective rate of treatment,the incidence of adverse reactions and serum sex hormone levels of the two groups were compared.Results The effective rate of the observation group was 93.88%,which was higher than that of control group with 79.17%,and the difference had statistical significance（P〈0.05）.The incidence of adverse reactions in observation group was 6.12%,which was lower than that of control group with 20.83%,and the difference had statistical significance（P〈0.05）.The levels of E2,PRL and LH in the observation group were lower than those in the control group,and the difference was statistically significant（P〈0.05）.Conclusion Breast I capsule can improve the clinical efficacy of patients with hyperplasia of mammary glands,reduce the incidence of adverse reactions,and improve the level of serum sex hormone.It is worth promoting.
出处
《中国医药科学》
2016年第22期74-76,共3页
China Medicine And Pharmacy
